Showing results (11-20 of 143) with videos related to
Sort By:
Pageof 15
Therapeutics and Clinical Risk Management|April 12, 2011
Broadening the use of antiretroviral therapy: the case for feline leukemia virusWillie M Greggs, Christine L Clouser, Steven E Patterson, et al.The Journal of General Virology|January 20, 2012
Discovery of drugs that possess activity against feline leukemia virusWillie M Greggs, Christine L Clouser, Steven E Patterson, et al.The Journal of General Virology|August 9, 2014
Novel inhibitors of human immunodeficiency virus type 2 infectivityLauren B Beach, Jonathan M Rawson, Baek Kim, et al.Antimicrobial Agents and Chemotherapy|August 19, 2015
Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesisJonathan M O Rawson, Sean R Landman, Cavan S Reilly, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 18, 2003
HIV mutagenesis and the evolution of antiretroviral drug resistanceLouis M ManskyVirology|April 2, 2003
Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replicationLouis M ManskyJournal of Molecular Biology|June 21, 2021
Distinct Antiretroviral Mechanisms Elicited by a Viral MutagenMegan Roth, Yumeng Z McDaniel, Michele B Daly, et al.Antimicrobial Agents and Chemotherapy|January 25, 2012
Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1Christine L Clouser, Colleen M Holtz, Mary Mullett, et al.Bioorganic & Medicinal Chemistry Letters|September 27, 2012
Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabineChristine L Clouser, Jay Chauhan, Matthew A Bess, et al.Viruses|July 22, 2018
The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant MutationsJosé O Maldonado, Louis M ManskyPageof 15